Operational Excellence: The Low-Hanging Fruit to Commercial Success

Even as new drug development focuses more on precision medicines, disconnected software applications force life science companies to continue struggling with imprecise workflows and outdated operating practices…reminiscent of the dark ages

Even with so much time, effort, and money on the line, many companies still rely on outdated technologies to support internal processes. It’s the biggest risk to the success of even the best-planned product launches. These legacy applications create information silos, causing friction in data exchange and gaps in knowledge that ultimately restrict collaboration. And as the number of stakeholders and outsourced partners increase throughout the drug development life cycle, companies cannot afford information bottlenecks that slow activity, or worse, jeopardize outcomes.

Without the right collaborative technologies, sharing information becomes a weekly chore of creating static status slides that quickly become outdated. Lack of visibility and insufficient clarity of accountability leads to frequent rework, which adds cycles of reiteration for deliverables. Without efficient mechanisms to capture and analyze data, many companies reinvent the wheel for each new drug candidate, unable to capitalize on the knowledge gained through past experiences.